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of genetic muscle disease affecting approximately 1 in 3500 males
(Flanigan, 2014). Boys with DMD carry mutations in the dystrophin
gene resulting in defective or absent dystrophin protein. Both skeletal
and cardiac muscles undergo progressive damage in this disease, with
most boys conﬁned to wheelchairs by age 12. There is currently no
cure for DMD and affected patients die from respiratory failure,
cardiomyopathy, or other complications at an average age of 25 years.
In this issue of EBioMedicine, Pelosi and colleagues present evidence
that blockade of interleukin-6 (IL-6) ameliorates muscle destruction
and weakness in a mouse model of DMD and suggest that this may
represent a novel therapeutic approach in humans.
In DMD, dystrophin deﬁciency disrupts the dystrophin–glycoprotein
complex, leading tomuscle ﬁber necrosis as well as a prominent inﬂam-
matory response. Although the inﬂammatory response may play a role
inmuscle repair, accumulating evidence suggests that it also contributes
to muscle damage (Spencer and Tidball, 2001). In the 1970s, recogni-
tion of this inﬂammatory response prompted Drachman and
colleagues to treat DMD patients with glucocorticoids (Drachman
et al., 1974). The improvements these investigators noted in some
DMD patients in an open-label trial have subsequently been conﬁrmed
in randomized, placebo-controlled clinical trials (Manzur et al., 2008).
However, glucocorticoids, which remain the only available treatment
for DMD, have relatively modest effect on the course of this fatal dis-
ease. Furthermore, these drugs have signiﬁcant side effects including
weight gain, osteoporosis, and increased risk of infection. Clearly,
more effective and safer treatments for DMD are desperately needed.
In an article in this issue of EBioMedicine, Pelosi and colleagues
observe that the inﬂammatory cytokine IL-6 is expressed at high levels
in the serum of boyswith DMDaswell as in inﬂammatory cells inﬁltrat-
ing their muscle tissue. Moreover, serum IL-6 levels were increased in
untreated DMD patients compared to those receiving treatment
with glucocorticoids. Taken together, these observations suggestedDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.02.014.
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In order to further study the possible role of IL-6 in mediating
muscle damage, these investigators utilized the mdx mouse model
of DMD. These mice lack functional dystrophin and, like boys with
DMD, develop a progressive muscular dystrophy that includes a
prominent inﬂammatory response. As in boys with DMD, Pelosi
and colleagues demonstrated that circulating levels of IL-6 are in-
creased and cells expressing high levels of IL-6 inﬁltrate the dia-
phragm muscles of mdx mice. To test whether blockade of IL-6
would ameliorate the dystrophic process in mdx mice, these mice
were treated with an antibody recognizing the IL-6 receptor. Com-
pared to untreated mdx mice, mice treated with the neutralizing
antibody had decreased myoﬁber necrosis, improved functional
performance after exercise on a treadmill, and evidence of a de-
creased inﬂammatory response in their muscle tissue.
Based on their ﬁndings, Pelosi and colleagues suggest that IL-6
inhibitors, which are already approved for children with systemic
juvenile idiopathic arthritis, should be considered for use in boys with
DMD. However, optimism about their potential effectiveness is
tempered by at least ﬁve considerations. First, another recent study by
Kostek et al. showed that IL-6 blockade increased muscle inﬂammation
and did not signiﬁcantly improve muscle function in mdxmice (Kostek
et al., 2012). These conﬂicting results may be due to differences in the
dosing regimens used in each study. If that's the case, it remains unclear
what the appropriate dosing regimen would be for DMD patients.
Second, boys with DMD frequently die as a result of cardiomyopathy
and the effect of IL-6 on cardiac muscle has not been studied. Third,
in addition to promoting a potentially harmful inﬂammatory milieu,
IL-6 has also been reported to play a role in muscle regeneration by
promoting myoblast differentiation (Serrano et al., 2008); any
therapeutic intervention aimed at blocking IL-6 in humans should
consider this dual role of IL-6. Fourth, although mdx mice have
been used extensively to understand the pathophysiology of DMD,
they have limitations as a model for testing the effectiveness of
therapeutic interventions (Partridge, 2013). Indeed, the literature
includes numerous examples of drugs that improved outcomes in
mouse models but did not have a similar effect in humans. And ﬁnally,
any therapy for DMD that does not involve repletion of dystrophin is
unlikely to cure this fatal disease. Despite these caveats, IL-6 blockade
certainly warrants further study as a potential treatment modality for
patients with DMD.ense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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